A top U.S. banking regulator is preparing to hand Citigroup a failing grade on its living-will plan, the latest rebuke for the megabank that has struggled to stay in the government’s good graces.

With fewer large deals, banks including JPMorgan are earning more fees from smaller outfits.

Bond investors have been spooked by Marine Le Pen’s euroskeptic and far-right party potentially winning the French legislative election. But recent cases of ousted populist politicians show that central banks are ultimately in charge.

The approval of Eli Lilly’s Alzheimer’s drug donanemab could help build momentum for Biogen’s struggling drug Leqembi.

UBS said it would repay investors 90% of their remaining fund stakes, but that the payments won’t affect its group results or capital .

The sharp rise in bond prices has pushed down the yield on the 10-year U.S. Treasury note, a benchmark for mortgage rates and other borrowing costs across the economy.